| Literature DB >> 29492716 |
Vineeta Shobha1, Saba Fathima2, Ravi Prakash3.
Abstract
Granulomatosis with polyangiitis (GPA) previously known as Wegener's granulomatosis is one of the forms of idiopathic systemic vasculitis. There is very scanty data available on GPA in Asian and Indian population. We studied data of 60 patients from southern India, diagnosed with GPA to describe the physical characteristics, the treatment, and outcome. Patients who fulfilled any two of the four criteria proposed by the American College of Rheumatology, and those with clinical features of GPA with ANCA positivity and histopathological confirmation, were included in the study. Disease activity and damage were assessed by Birmingham Vasculitis Activity Score v. 3 (BVAS v. 3) and Vasculitis Damage Index (VDI), respectively. Relapses were defined as recurrence of GPA of sufficient severity to require treatment or increase in the dose of treatment on a patient who was previously stable. Out of 60 patients, initial BVAS evaluation showed that 57 (95%) patients had severe disease and 3 (5%) patients had limited disease where median BVAS was 21.5 (range 17-44). Follow-up BVAS evaluation for severe disease showed that 13 (22.8%) patients continued with severe disease of which 9 patients did not survive, 24 (42.3%) had remission, 11 (19.2%) had persistent disease, and 9 (15.7%) were lost to follow-up. The mean VDI score was 2.5 ± 2. Renal involvement was established in 42 (70%) patients. Upper and lower respiratory involvement was seen in 38 (63%) patients. Nervous system involvement was noted in the 15 (25%) patients. Articular manifestations were seen in 16 (27%) patients. Diverse clinical manifestation delay early diagnosis and treatment of this potentially treatable vasculitis. Focused approach could expedite early diagnosis and can reduce the mortality.Entities:
Keywords: BVAS; GPA; Granulomatosis with polyangiitis; Vasculitis Damage Index; Wegener’s granulomatosis
Mesh:
Substances:
Year: 2018 PMID: 29492716 PMCID: PMC7102363 DOI: 10.1007/s10238-018-0492-7
Source DB: PubMed Journal: Clin Exp Med ISSN: 1591-8890 Impact factor: 3.984
Fig. 1Cavitatory lesions
Fig. 2Nodular lesions
Clinical manifestations
| System and symptoms | |
|---|---|
| Constitutional symptoms* | 48 (80%) |
| Renal involvement | 42 (70%) |
| Hypertension | 42 (100%) |
| Microscopic hematuria | 37 (89%) |
| Hypertension | 42 (100%) |
| Rapidly progressive renal failure | 28 (66%) |
| Nephrotic syndrome | 8 (19%) |
| Macroscopic hematuria | 5 (11%) |
| Asymptomatic urinary sediments | 7 (16%) |
| Respiratory involvement | 38 (63%) |
| Cough | 14 (36%) |
| Dyspnea | 8 (21%) |
| Hemoptysis | 6 (16%) |
| Nasal discharge | 5 (13%) |
| Chronic sinusitis | 4 (11%) |
| Ear discharge | 2 (5%) |
| Palate and nasal perforation | 2 (5%) |
| Diffuse alveolar hemorrhage | 2 (5%) |
| Chest X-ray and CT | 28 (47%) |
| Cavities | 8 (29%) |
| Nodules | 6 (21%) |
| Mucocutaneous lesions** | 29 (48%) |
| Articular manifestation | 16 (26%) |
| Neurological involvement | 15 (25%) |
| Peripheral neuropathy | 7 (46%) |
| Mononeuritis multiplex | 4 (27%) |
| Foot drop | 3 (20%) |
| Stroke | 1 (7%) |
| Ocular | 7 (11%) |
| Iritis | 3 (42%) |
| Uveitis | 3 (42%) |
| Cornea melting | 1 (16%) |
| Cardiac*** | 1 (1.6%) |
*Constitutional symptoms include fever, weight loss, and fatigue
**Mucocutaneous lesions included oral and cutaneous ulcers, cutaneous infarcts, and vasculitic lesions of the skin
***Cardiac involvement—intracardiac mass
Biopsies at various sites
| Biopsy site | |
|---|---|
| Renal | 34 |
| Skin | 9 |
| Lung | 7 |
| Nasal | 5 |
| Nerve | 4 |
| Palate | 2 |
| Mastoid antrum | 1 |
| Cardiac | 1 |
| Lacrimal | 1 |
Treatments and complications
| Induction treatment |
| % | Complications during treatment— |
|---|---|---|---|
| Steroids | 60 | 100 | Infections |
| IV cyclophosphamide | 50 | 83.3 | Bacterial infections and sepsis—30 |
| Oral cyclophosphamide | 8 | 13 | Candidiasis—18 |
| IVIG | 2 | 3.33 | H Zoster—6 |
| Plasmapheresis | 2 | 3.33 | Anemia—15 |
| Pancytopenia—7 | |||
| Alveolar hemorrhages—2 | |||
| Seizures—2 | |||
| Congestive cardiac failure—2 | |||
| CA Breast—1 | |||
| Others | |||
| Cushingoid habitus | |||
| Hair loss | |||
| Acne |
Causes of death
| Causes of death | Causes of death | |
|---|---|---|
| ESRD | 9 (82%) | 1—ESRO + Pancytopenia and sepsis |
| Pulmonary | 4 (36) | 2—Relapse with LRTI and sepsis |
| Infection (sepsis) | 3 (27%) | 3—Diffuse alveolar hemorrhage with ESRD (treated with plasmapheresis) |
| 4—Leucopenia with ESRD | ||
| 5—Diffuse alveolar hemorrhage | ||
| 6—Perinephric hematoma + ESRD | ||
| 7—Sepsis with ARDS + ESRD | ||
| 8—ESRD | ||
| 9—Pancytopenia + Sepsis + ESRD | ||
| 10—ESRD | ||
| 11—ESRD |
Comparison of published citations
| Fauci et al. [ | Hoffman et al. [ | Bambery et al. [ | Kumar et al. [ | Koldingsnes et al. [ | Kim et al. [ | Reinhold-Keller et al. [ | Holle et al. [ | Present series (India 2014) | |
|---|---|---|---|---|---|---|---|---|---|
| Number ( | 85 | 158 | 18 | 25 | 55 | 45 | 155 | 445 | 60 |
| Duration of analysis (years) | 21 | 24 | 25 | 12 | 15 | 26 | 27 | 36 | 14 |
| Age (mean) | 40.6 | 41 | 41.5 | 33.5 | 50 | 51.2 | 48 | 51 | 44 |
| M:F ratio | 1.3:1 | 1:1 | 1:1 | 1:1.7 | 1.6:1 | 1:1.3 | 1:1.04 | 1:1 | 1.4:1 |
| Age—range | 14–75 | 9–78 | 16–75 | 17–60 | 10–84 | 13.6–74.4 | 13–74 | 12–85 | 16–85 |
| Mean duration of follow-up | |||||||||
| (in months) | – | – | – | 60 | – | 67.4 | 84 | 72 | 56 |
| Range | – | – | – | 4–132 | – | 0.5–318.4 | – | 4–132 | |
| Duration of symptoms before diagnosis (months) | |||||||||
| Mean | 15 | 8 | 5.5 | 6 | 2.2 | – | – | 4.5 | |
| Range | 0–120 | 1–36 | 0.5–30 | 1–102 | 0–271 | – | – | 0–32 | |
| Clinical features (in percentage) | |||||||||
| Constitutional/fever | 34 | 23 | 89 | 64 | 85 | 88 | – | – | 80 |
| Upper respiratory—(nasopharynx/sinuses and ear) | 94 | 92 | 83 | 84 | 80 | 91.1 | 93 | 98 | 21 |
| Lower respiratory | 94 | 90 | 78 | 84 | 60 | 66.6 | 55 | 60 | 63 |
| Renal | 85 | 77 | 39 | 72 | 76 | 40 | 54 | 60 | 70 |
| Neurological | 22 | 23 | 28 | 4 | 35 | 37.7 | 21 | 33 | 25 |
| Articular | 67 | 67 | 55 | 44 | 64 | 35.5 | 61 | 73 | 27 |
| Ocular | 58 | 15 | 39 | 64 | 38 | 40 | 40 | 40 | 11 |
| Cardiac | 12 | 6 | – | 4 | 15 | – | 13 | 11 | 1 |
| Mucocutaneous | 45 | 46 | 39 | 32 | 31 | 28.8 | 21 | 26 | 48 |
| ANCA + VE | – | 88 | – | 70 | 88 | 64.4 | 84 | 81 | 93 |
| Mortality | 11.7 | 20 | 50 | – | 0.2 | 22 | 14 | 10 | 18 |
| VDI score | – | – | – | – | – | 3.5 ± 2 | – | – | 2.5 ± 2 |
| BVAS | – | – | – | 23 (4–46) | 13.1 (4–22) | – | – | 21.5 (17–44) | |